As of 2026-09-19, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -17.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 2,285.42 mil USD. NKTR's TTM EBITDA according to its financial statements is -130.55 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.8x - 16.3x | 11.6x |
| Forward P/E multiples | 11.9x - 15.8x | 14.2x |
| Fair Price | (46.51) - (61.50) | (50.47) |
| Upside | -169.3% - -191.7% | -175.2% |
| Date | EV/EBITDA |
| 2026-09-18 | -17.83 |
| 2026-09-17 | -17.83 |
| 2026-09-16 | -17.58 |
| 2026-09-15 | -17.39 |
| 2026-09-14 | -17.87 |
| 2026-09-11 | -18.19 |
| 2026-09-10 | -18.42 |
| 2026-09-09 | -19.12 |
| 2026-09-08 | -19.66 |
| 2026-09-04 | -19.34 |
| 2026-09-03 | -19.91 |
| 2026-09-02 | -18.97 |
| 2026-09-01 | -18.71 |
| 2026-08-31 | -18.61 |
| 2026-08-28 | -18.91 |
| 2026-08-27 | -19.43 |
| 2026-08-26 | -19.23 |
| 2026-08-25 | -19.54 |
| 2026-08-24 | -19.21 |
| 2026-08-21 | -19.30 |
| 2026-08-20 | -19.43 |
| 2026-08-19 | -19.83 |
| 2026-08-18 | -19.20 |
| 2026-08-17 | -18.95 |
| 2026-08-14 | -19.04 |
| 2026-08-13 | -19.79 |
| 2026-08-12 | -19.82 |
| 2026-08-11 | -19.68 |
| 2026-08-10 | -19.51 |
| 2026-08-07 | -19.93 |
| 2026-08-06 | -19.15 |
| 2026-08-05 | -19.06 |
| 2026-08-04 | -18.97 |
| 2026-08-03 | -18.41 |
| 2026-07-31 | -18.43 |
| 2026-07-30 | -18.63 |
| 2026-07-29 | -18.43 |
| 2026-07-28 | -18.46 |
| 2026-07-27 | -18.61 |
| 2026-07-24 | -18.44 |
| 2026-07-23 | -18.09 |
| 2026-07-22 | -18.08 |
| 2026-07-21 | -17.91 |
| 2026-07-20 | -16.92 |
| 2026-07-17 | -17.81 |
| 2026-07-16 | -17.49 |
| 2026-07-15 | -17.82 |
| 2026-07-14 | -17.52 |
| 2026-07-13 | -17.82 |
| 2026-07-10 | -18.35 |